EZH2 and prostate carcinoma: Recent researches have found that the expression of EZH2 is significantly upregulated in advanced prostate cancer with distant metastases, supporting the clinical relevance of poor diagnosis the emergence of NEPC in enzalutamide-induced models (Luo et al. 2019; Nadal et al. 2014; Varambally et al. 2002).